E. Merck KG board of partners has announced the appointment of new CEOs to Merck KGaA’s executive board, aiding its ongoing ...

Three children were executed by the Rwanda-backed M23 after they donned weapons and uniforms abandoned by the Congolese army ...

The German pharmaceutical-and-chemicals company on Tuesday said it appointed Jean-Charles Wirth as new chief executive of life science. Wirth succeeds Matthias Heinzel, who decided to not renew his ...

Germany's Merck KGaA said on Tuesday its lab equipment division and its pharmaceuticals division would be under new ...

The FDA on Tuesday signed off on SpringWorks Therapeutics’ mirdametinib—now to carry the brand name Gomekli—for the treatment ...

The Merck Foundation, in collaboration with African First Ladies, celebrates the International Day of Girls and Women in ...

Germany-based Merck KGaA (OTC:MKGAF) (OTC:MKKGY) reacted to press reports and confirmed advanced discussions with SpringWorks ...

As SpringWorks Therapeutics nears a key regulatory decision in the U.S., the Connecticut-based cancer and rare disease ...

Germany’s Merck KGaA is in advanced talks for a potential acquisition of SpringWorks Therapeutics, a U.S. biopharmaceutical ...

Merck KGaA, the German healthcare and technology group, is in advanced talks to acquire U.S. cancer and rare diseases drugmaker Springworks Therapeutics, according to people familiar with the matter.

Stamford-based SpringWorks Therapeutics, a commercial-stage biotech company developing treatments for rare diseases and cancer, is in “advanced talks” to be acquired by Germany’s Merck, according to ...

SpringWorks Therapeutics shares rose 36% after Reuters reported Germany's Merck KGaA is in advanced talks to buy the company. Shares were trading around $54.66. The stock is up 16% over the last year ...